Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Small cap

NGL Fine-Chem profit jumps 128% on strong domestic and export demand

Consolidated revenue rose 36% to ₹500.95 crore, while India sales more than doubled, lifting net profit to ₹48.13 crore.

4 earlier stories on NGL Fine-Chem Ltd.
Mkt cap₹1,847 cr
P/E38.38×
ROE7.39%
Debt / eq.0.27
Div yld0.06%
128% Surge in consolidated net profit for FY26

What's new

  • Consolidated revenue climbed 36% to ₹500.95 crore for the year ended March 31, 2026.
  • Net profit surged 128% to ₹48.13 crore, outpacing revenue growth.
  • India revenue more than doubled to ₹157.90 crore; rest-of-world jumped 78%.

Why this matters

Profit growth far outstripped revenue, pointing to a significant margin expansion. The India market, once a smaller part of the revenue mix, is now growing at a pace that alters the company's geographic dependency.

What we're watching

  • Whether the domestic surge represents a structural shift or a cyclical inventory build.
  • How the flat ₹1.75 dividend against a 128% profit jump affects shareholder returns.
  • Growth sustainability in Asia Pacific, which lagged other regions at 28%.

The full read

NGL Fine-Chem delivered a year where profit grew 128% to ₹48.13 crore, far outpacing the 36% rise in consolidated revenue to ₹500.95 crore. The numbers suggest a sharp margin expansion. The standout was India, where revenue more than doubled to ₹157.90 crore. That market, once a minor part of the mix, is now growing faster than the export base, which still dominates. Rest-of-world sales jumped 78% to ₹190.94 crore, while Asia Pacific grew 28%. The auditors signed off cleanly. The dividend stayed at ₹1.75 per share, so the payout ratio shrank even as cash generation improved. The question is whether the domestic acceleration is a permanent shift or a one-year cycle.

Questions answered

What caused profit to grow much faster than revenue?
The gap implies a strong expansion in operating margins, likely driven by the faster growth of domestic sales, which typically carry different margin characteristics than exports.
How did each geography contribute to the top line?
India was the standout, with revenue more than doubling to ₹157.90 crore. Rest of the world grew 78% to ₹190.94 crore, while Asia Pacific rose 28% to ₹144.45 crore.
What does the unchanged dividend signal?
The board recommended a final dividend of ₹1.75 per share, unchanged from the prior year. Given profit more than doubled, this cuts the payout ratio sharply.
Was the audit opinion clean?
Yes, the auditors issued an unmodified opinion on the consolidated results.
Mentioned: NGL Fine-Chem · FY26 audited results · ₹1.75 per share dividend
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

NGL Fine-Chem Ltd.

Pharmaceuticals
₹1,668 cr
P/E 34.67×

Latest quarter · Mar 2026

Sales₹149 cr
Net profit₹13 cr
Op. margin+14.3%
EPS₹21.83

Strength & growth

Debt / equity0.27×
Current ratio1.98×
Sales CAGR+17.9%
EPS CAGR+15.1%
  1. 21 May 2026 · 9:41 PM IST NGL Fine-Chem profit jumps 128% on strong domestic and export demand
  2. 51d ago NGL Fine-Chem profit jumps 128% as India revenue more than doubles
  3. 51d ago NGL Fine-Chem profit more than doubles to ₹48 cr on broad-based demand
  4. 52d ago NGL Fine-Chem profit surges 128% on broad geographic growth
  5. 52d ago NGL Fine-Chem profit surges 128% as Indian revenue doubles